1	Prevalence of Elevated Blood Pressure and Left Ventricular Hypertrophy in Adolescents with
2	Congenital Heart Disease
3	Aaron T. Walsh ^{1,4} , MD; Kan N. Hor, MD ^{1,4*} ; Mariah Eisner, MS ^{1,2} ; Mahmoud Kallash, MD ^{3,4} ; John
4	David Spencer, MD ^{3,4} ; Andrew H. Tran, MD, MS ^{1,4*}
5	* Equal contribution
6	¹ The Heart Center, Nationwide Children's Hospital, Columbus, OH
7	² Biostatistics Resource at Nationwide Children's Hospital, Columbus, OH
8	³ Division of Nephrology and Hypertension, Nationwide Children's Hospital, Columbus, OH
9	⁴ Department of Pediatrics, The Ohio State University, Columbus, OH
10	
11	Prevalence of HTN and LVH in Adolescents with CHD
12	
13	Corresponding author:
14	Andrew H. Tran, MD, MS
15	The Heart Center, Nationwide Children's Hospital, Tower Building, Suite T4147,
16	700 Children's Drive, Columbus, OH 43205, USA. Tel.: +1-614-722-0630; Fax: +1, 614-722-2549;
17	and rew.tran@nationwidechild rens.org
18	Total Word Count: 5,211

19 Abstract

20	Background: Left ventricular hypertrophy (LVH) associated with hypertension (HTN) is a
21	predictor of cardiovascular (CV) events in adulthood. LVH is defined using left ventricular mass
22	indexed to height ^{2.7} (LVMI-ht ^{2.7}) with current guidelines using the adult cutoff of 51 g/ht ^{2.7} ;
23	however, the pediatric cutoff is lower. Adults with congenital heart disease (CHD) have higher
24	rates of HTN compared to the general adult population. Data on the prevalence of elevated
25	blood pressure (SBP) in youths with CHD is limited. The aim of our study was to determine the
26	prevalence of elevated BP and LVH in adolescents with CHD.
27	Methods: We retrospectively analyzed echocardiograms from patients with CHD from 2012-
28	2019. Patients with biventricular CHD aged 13-17 years with documented BP, height, weight,
29	and measurement of LVMI-ht ^{2.7} were included. We defined LVH using the pediatric cutoff of
30	LVMI-ht ^{2.7} \ge 38.6 g/ht ^{2.7} . Patients were grouped by BP category into normotensive (NT, SBP <
31	120 mm Hg), Elevated BP (E-BP, 120 \leq SBP < 130 mm Hg), Stage 1 HTN (HTN-1, 130 \leq SBP < 140
32	mm Hg), and Stage 2 HTN (HTN-2, SBP \ge 140 mm Hg). Prevalence of LVH was reported in each
33	group defined as LVMI-HT ^{2.7} \geq 38.6 g/ht ^{2.7} .
34	Results: 855 patients were included. Mean (± standard deviation, SD) age was 15.5±1.5 years
35	with 485/855 (56.7%) male, SBP 117±13.5 mmHg, and LVMI-ht ^{2.7} 34.2±10.5 g/ht ^{2.7} . 493/855
36	(57.7%) were in the NT group, 214/855 (25%) in E-BP, 99/855 (11.6%) in HTN-1, and 49/855

37 (5.7%) in HTN-2. Prevalence of LVH increased with higher SBP with 96/493

38 (19.5%) in NT, 80/214 (37.4%) in E-BP, 32/99 (32.3%) in HTN-1, and 20/49 (40.8%) in HTN-

39	2. Of youths with LVH, 49/228 (21.5%) met adult criteria of \geq 51 g/ht ^{2.7} . Age, male sex, and body
40	mass index (BMI) percentile were significantly associated with increased LVMI-ht ^{2.7} .
41	Conclusions: Youths with CHD have a high prevalence of elevated BP, HTN, and LVH. BMI is a
42	significant risk factor for the development of LVH in this population. These findings support
43	early screening for HTN in this group because youths with CHD have baseline increased CV risk
44	that may be compounded by obesity and long-term HTN.
45	<u>Clinical Perspective</u>
46	• What is new?
47	\circ The prevalence of abnormal blood pressure and LVH in adolescents with CHD is
48	understudied and our data show that HTN and LVH are common in this
49	population.
50	\circ One-fifth of adolescents with biventricular congenital heart disease and left
51	ventricular hypertrophy met adult criteria for left ventricular hypertrophy.
52	What are the clinical implications?
53	\circ Left ventricular hypertrophy secondary to hypertension is linked to adverse
54	cardiac events in adulthood.
55	\circ Early screening and detection for abnormal blood pressure in the adolescent
56	congenital heart disease population may lead to earlier initiation of lifestyle
57	interventions or pharmacotherapy and mitigate long-term adverse clinical and
58	financial outcomes in an already vulnerable population.
59	

60 Introduction

61	The global prevalence of congenital heart disease (CHD) is estimated to be 1.8 cases per 100
62	live births ¹ and accounts for one-third of all congenital anomalies ² . With improvements in
63	prenatal detection, postnatal care, pharmacologic agents, interventional techniques, and
64	surgical outcomes, more patients born with CHD are living past the first decade of life. Adults
65	with CHD now comprise two-thirds of the total CHD population ³ and manifest several
66	cardiovascular (CV) risk factors at rates higher than the general adult population, including
67	systolic hypertension (HTN) ⁴ .
68	
69	Left ventricular hypertrophy (LVH) as detected by echocardiography has long been associated
70	with HTN and confers an increased risk of adverse CV events in adulthood. The Framingham
71	Heart Study demonstrated that increased left ventricular mass (LVM) in adults was
72	independently associated with CV disease, death from CV disease, and all-cause mortality even
73	after adjustment for traditional risk factors ⁵ . The prognostic ability of LVH for CV events has
74	held true across more diverse ethnic populations, the elderly, in those with essential HTN, and
75	following myocardial infarction ⁶⁻¹² with links to increased risk of stroke, heart failure, coronary
76	artery disease, and arrhythmia ^{6, 7, 12-14} . In the general adolescent population with essential
77	hypertension, a linear relationship was found between HTN and LVM ¹⁵ , with LVM values
78	associated with a fourfold increase for CV disease in adulthood ¹⁶ . However, the prevalence of
79	HTN and LVH in adolescents with CHD is less well-known. Therefore, the aim of our study was
80	to determine the prevalence of HTN and LVH in this ever-growing population.

81

82 Methods

83 Study Population

- 84 We performed a retrospective analysis of an echocardiogram database and the
- 85 Electronic Medical Record of adolescent patients aged 13-17 years with biventricular CHD

86 (excluding those patients with single ventricular or functionally single ventricular lesions such as

- 87 hypoplastic left heart syndrome, tricuspid atresia, and pulmonary atresia with intact ventricular
- 88 septum, or others who have required single-ventricle palliation) from 2012-2019 at Nationwide
- 89 Children's Hospital. We chose to study this age distribution as the blood pressure cutoffs in this
- population directly correlate with those in the adult population¹⁷ in which adverse CV outcomes
- are described. Only patients with documented blood pressure, height, weight, body mass index
- 92 (BMI), and echocardiographic data for LVM calculation at the time of their most recent
- 93 echocardiogram were included.
- 94

95 Echocardiogram Parameters and LVM

For the purposes of this study, the echocardiographic measurements were measured off MMode, a standard for LV quantification in our lab during this timeframe. Demographic data and
echocardiographic variables for assessment of LVH are included in **Table 1**. Measurements of
the interventricular septum (IVSd) and left ventricular posterior wall (LVPWd) were taken at
end-diastole. Left ventricular dimensions were taken at end-diastole (LVEDD) and end-systole
(LVESD). LVM was determined via the formula proposed by Devereux et al: 0.8x
(1.04x[(IVS+LVID+PWT)³-LVID³] + 0.6 grams¹⁸.

103	LVM was then indexed to body height to the power of 2.7 (LVMI-ht ^{2.7} =LVM/height ^{2.7}) to adjust
104	for differences in body size ^{18, 19} . LV function was assessed by left ventricular shortening fraction
105	(LVSF).

106

107 Blood Pressure Definitions and Categories

108 Patients were stratified by blood pressure category into normotensive (NT, SBP<120 mmHg),

elevated blood pressure (E-BP, 120≤SBP<130 mmHg), stage 1 HTN (HTN-1, 130≤SBP<140

110 mmHg), and stage 2 HTN (HTN-2, SBP≥140 mmHg) per the 2017 Clinical Practice Guideline

111 (CPG) for Screening and Management of Blood Pressure in Children and Adolescents¹⁷ utilizing

the automated blood pressure taken at the time of their most recent echocardiogram. The

prevalence of LVH was reported in each group using the pediatric cutoff for LVH of LVMI-ht^{2.7} \geq

114 38.6 g/ht^{2.7} which corresponds to the 95th percentile for LVMI-ht^{2.7} in children and increases

the sensitivity for detecting LVH before it reaches a level associated with CV events in

adulthood^{15, 20}. Results were also compared to the 2017 CPG recommendation of LVMI-ht^{2.7} \geq

117 51g/ht^{2.7} for LVH, which is the adult cutoff associated with increased risk for cardiovascular

118 events ²¹ but which is far above the 95th percentile values in pediatrics ¹⁷.

119

120 BMI stratification

BMI percentiles were obtained from the Centers for Disease Control and Prevention growth charts. BMI z-scores were calculated by BMIz=(BMI/M)L-1/(L*S), where L, M, and S are reference values from the growth chart for the corresponding child age and sex. BMI percentiles were calculated from z-scores based on the normal distribution. Subjects were

125	categorized based on BMI percentile as normal weight (BMI < 85th percentile), overweight
126	(85th percentile \leq BMI < 95th percentile), or obese (BMI \geq 95th percentile).
127	

128 Statistical analysis

129 Data were summarized using frequency (percentage) for categorical variables, mean (standard deviation, SD) for continuous symmetric variables, and median (interguartile range, IQR) for 130 continuous skewed variables. Data were quality checked and distributions were visualized using 131 132 bar and violin plots. For model stability, race groups were aggregated into white, black, or other 133 (includes American Indian, Asian, Hispanic, Native American, Pacific Islander, biracial, and other). Prevalence of LVH among each blood pressure group was calculated. Among 134 135 adolescents that met pediatric LVH criteria, the percentage also meeting the adult LVH criteria 136 was calculated. Pairwise comparisons were performed for the echocardiogram parameters 137 between each blood pressure category and adjusted for multiple comparisons utilizing the 138 Bonferroni correction. Univariable linear regression models were constructed for continuous outcomes LVMI-ht^{2.7}, LVEDD, LVESD, LVPWd, IVSd, LVSF, and LVEF. Predictor variables included 139 age, sex, race, continuous SBP, and BMI percentile. Multivariable linear regression models were 140 fit for each outcome with the same independent variables, using complete cases without 141 142 missing predictors. The interaction term between SBP and BMI percentile was also assessed 143 and removed from the model if not significantly associated with the outcome. P-values < 0.05 were considered statistically significant. All statistical analyses were performed in R version 4.0 144 145 (R Core Team, Vienna, Austria).

146

147 **Results**

148 Patient Characteristics

- A total of 855 patients met the inclusion criteria (56.7% male) with mean (SD) age 15.5 ± 1.5
- 150 years (range 13.0 to 17.9 years). Patient characteristics can be found in **Table 1**. The race of
- 151 patients was predominantly White (79.9%). BMI, BMI percentile, and body surface area (BSA)
- trended higher in the abnormal blood pressure groups. Over half of patients were NT (57.7%),
- 153 with 25%, 11.6% and 5.7% meeting criteria for E-BP, HTN-1, and HTN-2, respectively.
- 154

155 Echocardiogram Parameters

- 156 Those in the E-BP and HTN-1 groups had higher LVEDD values compared to NT (Table
- 157 **2)**. Patients with abnormal BP had thicker LVPWd and IVSd compared to NT subjects. LVMI-ht^{2.7}
- 158 increased across blood pressure categories and was significantly higher in the abnormal blood
- pressure groups compared to NT. One-third of patients in the HTN-1 and 41% of patients in the
- 160 HTN-2 category met criteria for LVH. Of the youths with LVH, one-fifth (21.5%) met the adult
- 161 criteria for LVH with LVMI-ht^{2.7} \geq 51g/ht^{2.7}. Ejection fraction was preserved and consistent
- 162 across blood pressure categories.
- 163

164 Univariable and Multivariable Linear Regression Models

165 Univariable linear regression demonstrated age, male sex, BMI percentile, and SBP were

- significantly associated with LVH (Table 3). After adjustment in a multivariable linear regression,
- age, male sex, and BMI percentile remained significant predictors of LVMI-ht^{2.7} while SBP no
- longer correlated **(Table 4).** In a subgroup analysis of patients with normal BMI, SBP was an

independent predictor of LVMI-ht^{2.7} (p=0.011) on univariable analysis, but lost significance in
 the adjusted model.

171

172 Discussion

173 HTN

There is a paucity of data related to HTN and LVH in the adolescent congenital heart disease 174 population. We found that in our large cohort of adolescents with biventricular CHD, over 40% 175 176 had abnormal blood pressure. LVM was linearly associated with elevated blood pressure such 177 that only 20% of those with normal blood pressure had LVH by echocardiography compared to 178 35% of those with HTN. The rates of abnormal blood pressure in our group were higher than those previously reported for youth in the general population²²⁻²⁶, which may reflect the impact 179 of the underlying CHD on vascular tone. Indeed, Mivelaz et al demonstrated elevated aortic 180 181 stiffness in a similar cohort of adolescents with biventricular CHD²⁷, which is a vascular marker linked to future cardiovascular morbidity and mortality²⁸. This is not surprising given that 182 patients with CHD often have several risk factors for HTN including chronic renal insufficiency as 183 well as changes in arterial wall architecture that places them at higher risk of abnormal blood 184 pressure^{29, 30}. High blood pressure did not remain a significant risk factor for LVH in 185 186 multivariable regression analysis. We suspect this may be due to a longitudinal effect of blood 187 pressure on LVM that may not be seen until the adult years. Nonetheless, we know that hypertensive youths are prone to becoming adults with HTN ³¹⁻³³ and that identification of 188 abnormal blood pressures in the formative years may play an important prognostic role. 189

- 190 Perhaps annual ambulatory blood pressure monitoring in adolescents with CHD would be best
- 191 practice to screen for those already experiencing elevated blood pressures.
- 192
- 193 LVH

LVMI-ht^{2.7} appeared to be higher in those with higher BP on univariate analysis consistent with 194 previous findings in children and adolescents without CHD³⁴. One-fifth of patients with LVH met 195 196 adult criteria which is higher than levels previously reported for hypertensive young patients without CHD¹⁶, suggesting a compounding effect of underlying CHD on the development of 197 LVH. Age, male sex, BMI percentile, and blood pressure were significantly associated with LVMI-198 ht^{2.7} using univariable analysis. After adjusting for variables in a multilinear regression model, 199 age, male sex, and BMI percentile remained significant predictors of LVMI-ht^{2.7} while SBP lost 200 201 its significance, similar to previous findings in adults by de Simone et al. ¹⁸. However, data from 202 the SHIP AHOY study group have demonstrated SBP to be a significant determinant of LVMIht^{2.7} in healthy adolescents after adjusting for covariates¹⁵. Their cohort age range skewed older 203 than the current data set, suggesting a longitudinal effect of SBP on LVMI-ht^{2.7} which may have 204 risen to significance on multivariate analysis in our cohort if given more time. 205

206

207 BMI

The association between obesity, HTN, and LVH in the general pediatric population is welldocumented³⁵⁻³⁸. Children without CHD with overweight or obesity and HTN were found to have higher LVM indices at baseline and longitudinally compared to those of healthy weight who were hypertensive³⁹. Our study of children with CHD mirrors these findings with one in five

patients having obesity and BMI percentile being significantly associated with LVMI-ht^{2.7}. This is 212 213 important because children with CHD can be at higher risk for future CV events compared to non-CHD children⁴⁰ so the presence of obesity and early echocardiographic changes may 214 215 further compound future risk in these patients. 216 Weight continues to prove itself to be a crucial factor in the development of LVH. Similar to our 217 findings, in a cohort of 160 pediatric patients from the Bogalusa Heart study, weight remained 218 219 the only significant predictor for LVM in multivariate analysis after controlling for age, sex, and SBP ⁴¹. Burke et al. found that adults in the MESA study who were obese had a two-fold 220 increased risk of having LVM exceeding the 80th percentile compared to those with a normal 221 222 body size after adjustment for traditional risk factors, making body size a potentially modifiable 223 risk factor for subclinical CV disease⁴².

224

Our study was novel in having a large cohort of patients inclusive of a large spectrum of 225 226 biventricular CHD. We also utilized the most up to date guidelines for characterizing HTN in the adolescent population¹⁷ which is felt to capture more accurately those with abnormal blood 227 pressures. Prior studies on HTN and LV geometry changes in CHD have focused primarily on 228 coarctation of the aorta and its associated long-term outcomes^{43, 44}. While our study included 229 230 patients with left ventricular outflow tract (LVOT) obstructions, the majority of documented LVOT gradients on the echocardiograms used for this study demonstrated no or mild residual 231 pressure gradient, indicating that a residual obstruction is less likely responsible for any 232 233 observed increase in LVM. This study broadens our understanding of the impact of HTN and

overweight/obesity on children with CHD. Our study highlights the need for early detection of 234 235 abnormal BP and obesity in patients with CHD to prevent progression of LVH to levels known to be associated with hard CV events. Knowledge of the risk for LVH in this age group becomes 236 increasingly important considering findings that elevated LVM can be found at blood pressures 237 below the current definition of pediatric HTN¹⁵. Furthermore, elevated blood pressure has 238 been associated with systolic and diastolic dysfunction^{45, 46} which may already be compromised 239 240 by the patient's CHD. With the knowledge of early abnormal blood pressure and evidence of 241 increased LVM in overweight and obese patients with CHD, it becomes vital to screen patients and to be vigilant about providing anticipatory guidance and considering pharmacological 242 intervention in patients who meet criteria. This is especially important in light of evidence that 243 regression in LVM leads to lesser risk of CV disease ⁸. Targeted diet and lifestyle 244 recommendations such as the Dietary Approaches to Stop Hypertension (DASH)¹⁷ and the 245 246 Cardiovascular Health Integrated Lifestyle Diet (CHILD) recommended by the American Academy of Pediatrics (AAP) ⁴⁷ should be stressed particularly in this patient population. 247 Physical activity recommendations should also be emphasized ⁴⁸ depending on appropriate 248 activity clearance by heart lesion. Current pediatric hypertension guidelines recommend yearly 249 250 ambulatory blood pressure monitor (ABPM) placement in patients with repaired aortic coarctation ¹⁷; however, ABPM can also be useful in screening other CHD patients for 251 252 hypertension.

253

254 Limitations

While our study is one of the largest to evaluate BP and LVMI-ht^{2.7} amongst the pediatric CHD 255 256 population, there are several inherent limitations that should be noted. Our study is a single center retrospective cohort study which limits the ability to determine causation for increased 257 258 LVM. We believe that with our large sample size, which encompasses all types of biventricular 259 CHD, we avoided selection bias that can accompany some retrospective studies. To that end, we did not stratify by types of CHD and it is possible that our population potentially includes a 260 larger percentage of patients with left ventricular outflow tract obstructive lesions which are 261 262 known to be risk factors for LVH. This will need to be further elucidated in future studies. Given 263 the descriptive nature of our work, whether patients were identified as hypertensive or if they were being actively treated for HTN was not investigated. Additionally, single time-point blood 264 265 pressures were utilized for our analysis. Serial blood pressure evaluation and incorporation of 266 ambulatory blood pressure monitoring data would further enhance our understanding of the 267 true prevalence of HTN in this cohort and provide insight into the timing of development of end-organ damage. Future studies should be aimed at longitudinal changes in blood pressure 268 269 and LVH and the impact of pharmacological intervention and social determinants on HTN, 270 obesity, and evidence of cardiac dysfunction in the pediatric CHD population. 271

272

273 Acknowledgements

274 Sources of Funding: None

275 Disclosures: No authors have relevant disclosures.

276

277 **References**

Global, regional, and national burden of congenital heart disease, 1990-2017: A 278 1. 279 systematic analysis for the global burden of disease study 2017. Lancet Child Adolesc 280 Health. 2020;4:185-200 van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, et al. 281 2. 282 Birth prevalence of congenital heart disease worldwide: A systematic review and metaanalysis. J Am Coll Cardiol. 2011;58:2241-2247 283 284 3. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. 285 286 *Circulation*. 2014;130:749-756 287 4. Moons P, Van Deyk K, Dedroog D, Troost E, Budts W. Prevalence of cardiovascular risk factors in adults with congenital heart disease. Eur J Cardiovasc Prev Rehabil. 288 289 2006;13:612-616 290 5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of 291 echocardiographically determined left ventricular mass in the framingham heart study. 292 N Engl J Med. 1990;322:1561-1566 293 Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, et al. The relationship of left 6. ventricular mass and geometry to incident cardiovascular events: The mesa (multi-294 ethnic study of atherosclerosis) study. J Am Coll Cardiol. 2008;52:2148-2155 295 7. 296 Kawel-Boehm N, Kronmal R, Eng J, Folsom A, Burke G, Carr JJ, et al. Left ventricular mass 297 at mri and long-term risk of cardiovascular events: The multi-ethnic study of atherosclerosis (mesa). Radiology. 2019;293:107-114 298 299 Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic 8. 300 significance of serial changes in left ventricular mass in essential hypertension. 301 Circulation. 1998;97:48-54 Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous 302 9. 303 relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580-586 304 Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, et al. Left 305 10. ventricular mass and cardiovascular morbidity in essential hypertension: The mavi 306 study. J Am Coll Cardiol. 2001;38:1829-1835 307 11. Gardin JM, McClelland R, Kitzman D, Lima JA, Bommer W, Klopfenstein HS, et al. M-308 309 mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the 310 311 cardiovascular health study). Am J Cardiol. 2001;87:1051-1057 312 12. Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, et al. Prognostic 313 implications of left ventricular mass and geometry following myocardial infarction: The valiant (valsartan in acute myocardial infarction) echocardiographic study. JACC 314 315 Cardiovasc Imaging. 2008;1:582-591 316 13. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular mass is a risk factor for the development of a depressed left 317

318 319		ventricular ejection fraction within five years: The cardiovascular health study. <i>J Am Coll Cardiol</i> , 2004:43:2207-2215
320	14	Levy D. Anderson KM. Savage DD. Balkus SA. Kannel WB. Castelli WP. Risk of ventricular
321	±	arrhythmias in left ventricular hypertrophy: The framingham heart study Am I Cardiol
322		1987·60·560-565
323	15	Urbina FM Mendizabal B Becker RC Daniels SR Falkner BE Hamdani G et al
324	13.	Association of blood pressure level with left ventricular mass in adolescents
325		Hypertension, 2019:74:590-596
326	16.	Daniels SR. Loggie IM, Khoury P, Kimball TR. Left ventricular geometry and severe left
327	10.	ventricular hypertrophy in children and adolescents with essential hypertension
328		Circulation, 1998:97:1907-1911
329	17.	Elvnn IT. Kaelber DC. Baker-Smith CM. Blowey D. Carroll AF. Daniels SR. et al. Clinical
330	-/.	practice guideline for screening and management of high blood pressure in children and
331		adolescents. <i>Pediatrics</i> . 2017:140
332	18.	de Simone G. Devereux RB. Roman MJ. Alderman MH. Laragh JH. Relation of obesity and
333		gender to left ventricular hypertrophy in normotensive and hypertensive adults.
334		Hypertension. 1994:23:600-606
335	19.	de Simone G. Daniels SR. Devereux RB. Mever RA. Roman MJ. de Divitiis O. et al. Left
336		ventricular mass and body size in normotensive children and adults: Assessment of
337		allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251-1260
338	20.	Daniels SR, Kimball TR, Morrison JA, Khoury P, Meyer RA. Indexing left ventricular mass
339		to account for differences in body size in children and adolescents without
340		cardiovascular disease. Am J Cardiol. 1995;76:699-701
341	21.	de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth
342		on variability of left ventricular mass: Assessment of allometric signals in adults and
343		children and their capacity to predict cardiovascular risk. Journal of the American
344		College of Cardiology. 1995;25:1056-1062
345	22.	McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. Prevalence of
346		hypertension and pre-hypertension among adolescents. The Journal of Pediatrics.
347		2007;150:640-644.e641
348	23.	Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and
349		adolescents. Jama. 2007;298:874-879
350	24.	Chiolero A, Cachat F, Burnier M, Paccaud F, Bovet P. Prevalence of hypertension in
351		schoolchildren based on repeated measurements and association with overweight. J
352		Hypertens. 2007;25:2209-2217
353	25.	Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the
354		prevalence of hypertension in school-aged children. Pediatrics. 2004;113:475-482
355	26.	Moore WE, Stephens A, Wilson T, Wilson W, Eichner JE. Body mass index and blood
356		pressure screening in a rural public school system: The healthy kids project. Prev Chronic
357		Dis. 2006;3:A114-A114
358	27.	Mivelaz Y, Leung MT, Zadorsky MT, De Souza AM, Potts JE, Sandor GG. Noninvasive
359		assessment of vascular function in postoperative cardiovascular disease (coarctation of
360		the aorta, tetralogy of fallot, and transposition of the great arteries). Am J Cardiol.
361		2016;118:597-602

Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-362 28. 363 cause mortality with arterial stiffness: A systematic review and meta-analysis. Journal of 364 the American College of Cardiology. 2010;55:1318-1327 365 29. Morgan CJ, Zappitelli M, Robertson CMT, Alton GY, Sauve RS, Joffe AR, et al. Risk factors for and outcomes of acute kidney injury in neonates undergoing complex cardiac 366 surgery. The Journal of Pediatrics. 2013;162:120-127.e121 367 30. Roche SL, Silversides CK. Hypertension, obesity, and coronary artery disease in the 368 survivors of congenital heart disease. Can J Cardiol. 2013;29:841-848 369 370 31. Tirosh A, Afek A, Rudich A, Percik R, Gordon B, Ayalon N, et al. Progression of normotensive adolescents to hypertensive adults: A study of 26,980 teenagers. 371 Hypertension. 2010;56:203-209 372 373 32. Sun SS, Grave GD, Siervogel RM, Pickoff AA, Arslanian SS, Daniels SR. Systolic blood 374 pressure in childhood predicts hypertension and metabolic syndrome later in life. 375 Pediatrics. 2007;119:237-246 376 33. Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: The bogalusa heart 377 378 study. Am J Hypertens. 1995;8:657-665 379 34. Stabouli S, Kotsis V, Rizos Z, Toumanidis S, Karagianni C, Constantopoulos A, et al. Left ventricular mass in normotensive, prehypertensive and hypertensive children and 380 adolescents. Pediatr Nephrol. 2009;24:1545-1551 381 Lurbe E, Alvarez V, Liao Y, Tacons J, Cooper R, Cremades B, et al. The impact of obesity 382 35. 383 and body fat distribution on ambulatory blood pressure in children and adolescents. Am J Hypertens. 1998;11:418-424 384 Movahed M-R, Bates S, Strootman D, Sattur S. Obesity in adolescence is associated with 385 36. 386 left ventricular hypertrophy and hypertension. Echocardiography. 2011;28:150-153 Sivanandam S, Sinaiko AR, Jacobs DR, Steffen L, Moran A, Steinberger J. Relation of 387 37. 388 increase in adiposity to increase in left ventricular mass from childhood to young 389 adulthood. The American Journal of Cardiology. 2006;98:411-415 390 38. Mensah GA, Treiber FA, Kapuku GK, Davis H, Barnes VA, Strong WB. Patterns of body fat deposition in youth and their relation to left ventricular markers of adverse 391 cardiovascular prognosis. The American journal of cardiology. 1999;84:583-588 392 Brady TM, Appel LJ, Holmes KW, Fivush B, Miller ER, 3rd. Association between adiposity 393 39. and left ventricular mass in children with hypertension. Journal of clinical hypertension 394 (Greenwich, Conn.). 2016;18:625-633 395 396 40. Wang T, Chen L, Yang T, Huang P, Wang L, Zhao L, et al. Congenital heart disease and 397 risk of cardiovascular disease: A meta-analysis of cohort studies. J Am Heart Assoc. 398 2019;8:e012030 399 41. Urbina EM, Gidding SS, Bao W, Pickoff AS, Berdusis K, Berenson GS. Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults 400 in the bogalusa heart study. Circulation. 1995;91:2400-2406 401 402 42. Burke GL, Bertoni AG, Shea S, Tracy R, Watson KE, Blumenthal RS, et al. The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease: The multi-403 404 ethnic study of atherosclerosis. Arch Intern Med. 2008;168:928-935

405	43.	Gillett C, Wong A, Wilson DG, Wolf AR, Martin RP, Kenny D. Underrecognition of
406		aorta. <i>Rediatric Cardiology</i> 2011:32:202-205
407	ЛЛ	Preshitero P. Demarie D. Villani M. Perinetto FA. Riva G. Orzan F. et al. Long term results
400	44.	(15-30 years) of surgical repair of aortic coarctation <i>Br Heart I</i> 1987:57:462-467
409	45	Zamojska I. Njowjadomska Jarosik K. Wosjak A. Linjoc P. Stanczyk I. Myocardial
410	45.	dysfunction measured by tissue depaler echecardiography in children with primary
411		arterial hyportension Kardial Pal 2015:72:104 200
412	16	Tran AH, Elyph IT, Packer PC, Daniels SP, Falkner PE, Forguson M, et al. Subclinical
415	40.	systelic and diactalic dysfunction is avident in youth with algorithd blood pressure
414		Systolic and diastolic dystaliction is evident in youth with elevated blood pressure.
415	17	Typer Lension. 2020,75.1551-1550
410	47.	Adelessents National Heart L. Plead L. Expert panel on integrated guidelines for
417 110		addiescents, National Healt L, blood I. Expert panel of integrated guidelines for
410		Dediatrice 2011:129 Suppl E:S212 256
419	10	Pediatrics. 2011,128 Suppl 3.3213-230 Diarcy KL Trojano PD Ballard PM Carlson SA Fulton IE Galuska DA at al. The physical
420	40.	activity guidelines for americans. Jama, 2018;320:2020-2028
421		activity guidelines for americans. Junia. 2018,320.2020-2028
422		
122		
425		
424		
125		
423		
426		
427		
427		
428		
420		
429		
430		
121		
431		
432		

Tables 433

434

Table 1. Subject characteristics 435

Characteristic	Overall N = 855 ¹	Normotensive N = 493 ¹	Elevated N = 214 ¹	Stage 1 HTN N = 99 ¹	Stage 2 HTN N = 49 ¹
Age (years)	15.48 (1.46)	15.32 (1.47)	15.59 (1.51)	15.91 (1.20)	15.64 (1.37)
Sex					
Female	364 (42.9%)	243 (49.6%)	77 (36.3%)	28 (28.3%)	16 (33.3%)
Male	485 (57.1%)	247 (50.4%)	135 (63.7%)	71 (71.7%)	32 (66.7%)
Race					
White	642 (81.9%)	371 (82.1%)	156 (79.6%)	78 (83.9%)	37 (86.0%)
Black	112 (14.3%)	66 (14.6%)	30 (15.3%)	11 (11.8%)	5 (11.6%)
Other	30 (3.8%)	15 (3.3%)	10 (5.1%)	4 (4.3%)	1 (2.3%)
Height (cm)	165 (13)	163 (13)	168 (13)	170 (12)	169 (11)
Body surface area (m ²⁾	1.71 (0.31)	1.62 (0.28)	1.78 (0.28)	1.87 (0.28)	1.96 (0.40)
Weight (kg)	61 (52, 73)	56 (48, 66)	66 (56, 78)	71 (61, 85)	82 (63, 100)
BMI (kg/m ²)	22.0 (19.2 <i>,</i> 25.9)	20.7 (18.5 <i>,</i> 24.0)	23.0 (19.9 <i>,</i> 26.8)	24.4 (21.2, 29.3)	27.3 (21.9, 32.6)
BMI percentile (%)	68 (37, 92)	60 (29, 84)	77 (48, 93)	86 (59, 96)	95 (78 <i>,</i> 98)
BMI category					
Normal	570 (67.1%)	377 (76.9%)	129 (60.8%)	48 (48.5%)	16 (33.3%)
Overweight	127 (15.0%)	59 (12.0%)	37 (17.5%)	22 (22.2%)	9 (18.8%)
Obese	152 (17.9%)	54 (11.0%)	46 (21.7%)	29 (29.3%)	23 (47.9%)
Systolic blood pressure (mm Hg)	117 (108, 126)	110 (104, 114)	124 (122 <i>,</i> 126)	133 (131, 136)	146 (142 <i>,</i> 152)
Diastolic blood pressure (mm Hg) ¹ Mean (SD); n (%); Medi	64 (59, 70) ans (IQR)	62 (58, 68)	66 (60, 72)	67 (60, 76)	72 (64, 80)

436

*HTN, hypertension; BMI, body mass index; SD, standard deviation; IQR, interquartile range

437 Table 2. Echocardiogram Parameters

Characteristic	Overall N = 855 ¹	Normotensive N = 493 ¹	Elevated N = 214 ¹	Stage 1 HTN N = 99 ¹	Stage 2 HTN N = 49 ¹	P value
LVEDD (cm)	4.80 (4.39 <i>,</i> 5.20)	4.70 (4.30, 5.10)	4.88 (4.40 <i>,</i> 5.30)	5.00 (4.70, 5.38)	4.80 (4.50 <i>,</i> 5.20)	< 0.05 ^{2,3}
LVESD (cm)	3.00 (2.70, 3.30)	2.96 (2.60, 3.28)	3.08 (2.79, 3.38)	3.00 (2.77, 3.30)	2.97 (2.70, 3.30)	NS
LVPWd (cm)	0.80 (0.70, 0.90)	0.78 (0.69, 0.85)	0.81 (0.74 <i>,</i> 0.90)	0.85 (0.75, 0.94)	0.90 (0.80, 1.00)	< 0.05 ^{2,3,4}
IVSd (cm)	0.80 (0.70, 0.90)	0.80 (0.70, 0.90)	0.90 (0.72 <i>,</i> 0.96)	0.90 (0.80, 0.95)	1.00 (0.80, 1.06)	< 0.05 ^{2,3,4}
LVMI Ht ^{2.7} (g/ht ^{2.7})	33 (27, 39)	31 (26, 37)	35 (28, 43)	35 (29, 41)	36 (32, 44)	< 0.05 ^{2,3,4}
LVSF (%)	36.7 (33.3, 41.2)	36.4 (33.0, 40.7)	36.2 (33.3 <i>,</i> 41.2)	39.4 (35.9, 42.9)	39.0 (35.1 <i>,</i> 43.3)	< 0.05 ³
LVEF (%)	65 (60, 68)	64 (60, 67)	66 (60, 70)	65 (61, 70)	65 (61, 68)	NS

¹ Medians (IQR), ²Adjusted pairwise p-value <0.05 when NT compared to E-BP, ³Adjusted pairwise p-value <0.05 when NT compared to HTN-1, ⁴Adjusted pairwise p-value <0.05 when NT compared to HTN-2; NS, Non-significant pairwise p-value when NT compared to BP categories

*HTN, hypertension; BMI, body mass index; LVEDD, left ventricular end-diastolic dimension;

439 LVESD, left ventricular end-systolic dimension; LVPWd, left ventricular posterior wall thickness

in diastole; IVSd, interventricular septal thickness in diastole; LVMI Ht2.7; left ventricular mass

441 indexed to height to the power of 2.7; LVSF, left ventricular shortening fraction; LVEF, left

ventricular ejection fraction; SD, standard deviation; IQR, interquartile range. Values given as

443 medians and IQR.

444 Table 3. Univariable linear regression model for LVMI-ht^{2.7}

Characteristic	Ν	Beta	95% Cl ¹	p-value
Age (years)	855	0.84	0.35, 1.3	<0.001
Sex	849			
Female		—	—	
Male		2.7	1.3, 4.2	<0.001
Race	784			
White		_	_	
Black		2.0	-0.08, 4.2	0.060
Other		1.6	-2.2, 5.5	0.4
BMI percentile (%)	849	0.12	0.10, 0.14	<0.001
Systolic blood pressure, 10 mm Hg increase	855	1.4	0.89, 1.9	<0.001
¹ CI = Confidence Interval				
*LVMI-ht ^{2.7} ; left ventricular mass indexed to heigh	nt to the po	wer of 2	2.7	

452 Table 4. Multivariable linear regression model for LVMI-ht^{2.7}

Characteristic	Beta	95% Cl ¹	p-value
Age (years)	0.77	0.30, 1.2	0.001
Sex			
Female	—	_	
Male	2.7	1.3, 4.1	<0.001
Race			
White	_	_	
Black	1.7	-0.21, 3.7	0.080
Other	1.9	-1.7, 5.5	0.3
BMI percentile (%)	0.11	0.09, 0.14	<0.001
Systolic blood pressure, 10 mm Hg increase	0.26	-0.29, 0.81	0.4

453 *LVMI-ht^{2.7}, left ventricular mass indexed to height to the power of 2.7; BMI, body mass index